Annexon Inc. (ANNX) NASDAQ
$7.81 0.93 (13.52%)
Market Cap: $612.06M
As of 03/27/24 04:00 PM EDT. Market closed.
Annexon Inc. (ANNX)
NASDAQ
$7.81
0.93 (13.52%)
Market Cap: $612.06M
As of 03/27/24 04:00 PM EDT. Market closed.
our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration ... read more
our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd). read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Feb 20, 2024 | Sale | $5.53 | 2,593 | 14,339 | 82,058 | Feb 21, 2024, 04:31 PM |
Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Feb 12, 2024 | Sale | $5.53 | 1,349 | 7,460 | 48,592 | Feb 14, 2024, 07:59 PM |
Love Douglas | PRESIDENT AND CEO | Feb 12, 2024 | Sale | $5.54 | 5,782 | 32,032 | 196,121 | Feb 14, 2024, 07:56 PM |
Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Feb 12, 2024 | Sale | $5.54 | 1,809 | 10,022 | 45,651 | Feb 14, 2024, 07:54 PM |
Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Feb 12, 2024 | Sale | $5.54 | 1,810 | 10,027 | 36,075 | Feb 14, 2024, 07:52 PM |
Yednock Ted | EVP & Chief Innovation Officer | Dec 27, 2023 | Option Exercise | $1.63 | 21,000 | 34,176 | 58,885 | Jan 23, 2024, 05:00 PM |
Yednock Ted | EVP & Chief Innovation Officer | Dec 27, 2023 | Sale | $4.52 | 21,000 | 94,966 | 37,885 | Jan 23, 2024, 05:00 PM |
Yednock Ted | EVP & Chief Innovation Officer | Jul 11, 2023 | Sale | $3.84 | 1,057 | 4,055 | 37,885 | Jan 23, 2024, 05:00 PM |
Overdorf Michael | EVP & Chief Business Officer | Jul 11, 2023 | Sale | $3.84 | 978 | 3,752 | 45,802 | Jan 23, 2024, 04:58 PM |
Lew Jennifer | EVP & Chief Financial Officer | Jul 11, 2023 | Sale | $3.84 | 1,057 | 4,055 | 47,460 | Jan 23, 2024, 04:57 PM |
Yednock Ted | EVP & Chief Innovation Officer | Dec 27, 2023 | Option Exercise | $1.63 | 21,000 | 34,176 | 21,000 | Dec 29, 2023, 04:12 PM |
Yednock Ted | EVP & Chief Innovation Officer | Dec 27, 2023 | Sale | $4.52 | 21,000 | 94,966 | 0 | Dec 29, 2023, 04:12 PM |
Satter Muneer A | Director | Dec 26, 2023 | Buy | $2.88 | 350,000 | 1,008,000 | 7,406,024 | Dec 28, 2023, 04:30 PM |
Bain Capital Life Sciences Investors, LLC | 10% Owner | May 25, 2023 | Buy | $2.13 | 300,000 | 639,720 | 5,701,926 | May 30, 2023, 09:54 PM |
Love Douglas | President & CEO | Feb 15, 2023 | Sale | $5.87 | 6,571 | 38,564 | 197,646 | Feb 17, 2023, 05:12 PM |
Overdorf Michael | EVP & Chief Business Officer | Feb 14, 2023 | Sale | $6.30 | 144 | 907 | 27,805 | Feb 15, 2023, 07:00 PM |
Overdorf Michael | EVP & Chief Business Officer | Feb 13, 2023 | Sale | $6.30 | 1,501 | 9,461 | 27,949 | Feb 15, 2023, 07:00 PM |
Lew Jennifer | EVP & Chief Financial Officer | Feb 14, 2023 | Sale | $6.30 | 166 | 1,046 | 29,542 | Feb 15, 2023, 06:59 PM |
Lew Jennifer | EVP & Chief Financial Officer | Feb 13, 2023 | Sale | $6.31 | 1,742 | 10,989 | 29,708 | Feb 15, 2023, 06:59 PM |
Satter Muneer A | Director | Feb 10, 2023 | Buy | $6.80 | 2,647,058 | 17,999,995 | 7,056,024 | Feb 14, 2023, 04:31 PM |
Satter Muneer A | Director | Jul 07, 2022 | Buy | $3.84 | 2,453,988 | 9,423,314 | 4,408,966 | Jul 11, 2022, 08:42 PM |
Love Douglas | President & CEO | Apr 14, 2022 | Buy | $2.45 | 60,000 | 146,814 | 200,942 | Apr 18, 2022, 07:04 PM |
Love Douglas | President & CEO | Nov 11, 2021 | Option Exercise | $1.54 | 100,942 | 155,503 | 100,942 | Nov 15, 2021, 06:05 PM |
Love Douglas | President & CEO | Sep 16, 2021 | Option Exercise | $1.41 | 7,500 | 10,572 | 7,500 | Sep 20, 2021, 05:46 PM |
Love Douglas | President & CEO | Sep 16, 2021 | Sale | $22.05 | 7,500 | 165,341 | 0 | Sep 20, 2021, 05:46 PM |
Yednock Ted | EVP & Chief Scientific Officer | Sep 13, 2021 | Option Exercise | $1.68 | 16,190 | 27,225 | 16,190 | Sep 15, 2021, 06:35 PM |
Yednock Ted | EVP & Chief Scientific Officer | Sep 13, 2021 | Sale | $20.00 | 16,190 | 323,860 | 0 | Sep 15, 2021, 06:35 PM |
Lew Jennifer | EVP & Chief Financial Officer | Sep 13, 2021 | Option Exercise | $7.49 | 3,500 | 26,210 | 5,500 | Sep 15, 2021, 06:35 PM |
Lew Jennifer | EVP & Chief Financial Officer | Sep 13, 2021 | Sale | $20.01 | 3,500 | 70,034 | 2,000 | Sep 15, 2021, 06:35 PM |
Yednock Ted | EVP & Chief Scientific Officer | Jun 03, 2021 | Option Exercise | $1.41 | 15,000 | 21,144 | 15,000 | Jun 07, 2021, 04:47 PM |
Yednock Ted | EVP & Chief Scientific Officer | Jun 03, 2021 | Sale | $21.49 | 15,000 | 322,325 | 2,184 | Jun 07, 2021, 04:47 PM |
Love Douglas | President & CEO | Apr 01, 2021 | Option Exercise | $1.41 | 500 | 705 | 500 | Apr 02, 2021, 12:31 PM |
Love Douglas | President & CEO | Mar 31, 2021 | Option Exercise | $1.41 | 7,102 | 10,011 | 7,102 | Apr 02, 2021, 12:31 PM |
Love Douglas | President & CEO | Apr 01, 2021 | Sale | $28.08 | 500 | 14,041 | 300 | Apr 02, 2021, 12:31 PM |
Love Douglas | President & CEO | Mar 31, 2021 | Sale | $28.11 | 7,102 | 199,621 | 0 | Apr 02, 2021, 12:31 PM |
Love Douglas | President & CEO | Mar 29, 2021 | Option Exercise | $1.41 | 3,750 | 5,286 | 3,750 | Mar 31, 2021, 04:04 PM |
Love Douglas | President & CEO | Mar 30, 2021 | Option Exercise | $1.41 | 3,750 | 5,286 | 3,750 | Mar 31, 2021, 04:04 PM |
Love Douglas | President & CEO | Mar 29, 2021 | Sale | $25.42 | 3,750 | 95,334 | 900 | Mar 31, 2021, 04:04 PM |
Love Douglas | President & CEO | Mar 30, 2021 | Sale | $24.52 | 3,750 | 91,966 | 1,850 | Mar 31, 2021, 04:04 PM |
Yednock Ted | EVP & Chief Scientific Officer | Mar 25, 2021 | Option Exercise | $1.68 | 16,175 | 27,148 | 16,175 | Mar 29, 2021, 05:10 PM |
Yednock Ted | EVP & Chief Scientific Officer | Mar 25, 2021 | Sale | $28.80 | 16,175 | 465,770 | 5,917 | Mar 29, 2021, 05:10 PM |
Keswani Sanjay | EVP & Chief Medical Officer | Mar 24, 2021 | Option Exercise | $7.49 | 3,995 | 29,917 | 3,995 | Mar 26, 2021, 05:52 PM |
Keswani Sanjay | EVP & Chief Medical Officer | Mar 24, 2021 | Sale | $30.17 | 3,995 | 120,512 | 0 | Mar 26, 2021, 05:52 PM |
Lew Jennifer | EVP & Chief Financial Officer | Mar 23, 2021 | Option Exercise | $7.49 | 5,000 | 37,443 | 7,000 | Mar 25, 2021, 07:31 PM |
Lew Jennifer | EVP & Chief Financial Officer | Mar 23, 2021 | Sale | $28.44 | 5,000 | 142,176 | 5,600 | Mar 25, 2021, 07:31 PM |
Clarus Lifesciences III, L.P. | 10% Owner | Jul 28, 2020 | Buy | $17.00 | 200,000 | 3,400,000 | 2,730,635 | Jul 30, 2020, 08:00 PM |
Bain Capital Life Sciences Investors, LLC | 10% Owner | Jul 28, 2020 | Buy | $17.00 | 400,000 | 6,800,000 | 3,241,628 | Jul 28, 2020, 04:45 PM |
Lew Jennifer | EVP & Chief Financial Officer | Jul 28, 2020 | Buy | $17.00 | 2,000 | 34,000 | 2,000 | Jul 28, 2020, 04:18 PM |
Satter Muneer A | Director | Jul 28, 2020 | Buy | $17.00 | 200,000 | 3,400,000 | 1,954,978 | Jul 28, 2020, 04:17 PM |
Flynn James E | 10% Owner | Jul 28, 2020 | Buy | $17.00 | 350,000 | 5,950,000 | 808,914 | Jul 28, 2020, 12:54 PM |
Flynn James E | 10% Owner | Jul 28, 2020 | Buy | $17.00 | 350,000 | 5,950,000 | 808,914 | Jul 28, 2020, 12:54 PM |
Owner | Relationship | Date | Value($) |
Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 02/20/2024 | 14,339 |
Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 02/12/2024 | 7,460 |
Love Douglas | PRESIDENT AND CEO | 02/12/2024 | 32,032 |
Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 02/12/2024 | 10,022 |
Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 02/12/2024 | 10,027 |
Yednock Ted | EVP & Chief Innovation Officer | 12/27/2023 | 34,176 |
Yednock Ted | EVP & Chief Innovation Officer | 12/27/2023 | 94,966 |
Yednock Ted | EVP & Chief Innovation Officer | 07/11/2023 | 4,055 |
Overdorf Michael | EVP & Chief Business Officer | 07/11/2023 | 3,752 |
Lew Jennifer | EVP & Chief Financial Officer | 07/11/2023 | 4,055 |
Yednock Ted | EVP & Chief Innovation Officer | 12/27/2023 | 34,176 |
Yednock Ted | EVP & Chief Innovation Officer | 12/27/2023 | 94,966 |
Satter Muneer A | Director | 12/26/2023 | 1,008,000 |
Bain Capital Life Sciences Investors, LLC | 10% Owner | 05/25/2023 | 639,720 |
Love Douglas | President & CEO | 02/15/2023 | 38,564 |
Overdorf Michael | EVP & Chief Business Officer | 02/14/2023 | 907 |
Overdorf Michael | EVP & Chief Business Officer | 02/13/2023 | 9,461 |
Lew Jennifer | EVP & Chief Financial Officer | 02/14/2023 | 1,046 |
Lew Jennifer | EVP & Chief Financial Officer | 02/13/2023 | 10,989 |
Satter Muneer A | Director | 02/10/2023 | 17,999,995 |
Satter Muneer A | Director | 07/07/2022 | 9,423,314 |
Love Douglas | President & CEO | 04/14/2022 | 146,814 |
Love Douglas | President & CEO | 11/11/2021 | 155,503 |
Love Douglas | President & CEO | 09/16/2021 | 10,572 |
Love Douglas | President & CEO | 09/16/2021 | 165,341 |
Yednock Ted | EVP & Chief Scientific Officer | 09/13/2021 | 27,225 |
Yednock Ted | EVP & Chief Scientific Officer | 09/13/2021 | 323,860 |
Lew Jennifer | EVP & Chief Financial Officer | 09/13/2021 | 26,210 |
Lew Jennifer | EVP & Chief Financial Officer | 09/13/2021 | 70,034 |
Yednock Ted | EVP & Chief Scientific Officer | 06/03/2021 | 21,144 |
Yednock Ted | EVP & Chief Scientific Officer | 06/03/2021 | 322,325 |
Love Douglas | President & CEO | 04/01/2021 | 705 |
Love Douglas | President & CEO | 03/31/2021 | 10,011 |
Love Douglas | President & CEO | 04/01/2021 | 14,041 |
Love Douglas | President & CEO | 03/31/2021 | 199,621 |
Love Douglas | President & CEO | 03/29/2021 | 5,286 |
Love Douglas | President & CEO | 03/30/2021 | 5,286 |
Love Douglas | President & CEO | 03/29/2021 | 95,334 |
Love Douglas | President & CEO | 03/30/2021 | 91,966 |
Yednock Ted | EVP & Chief Scientific Officer | 03/25/2021 | 27,148 |
Yednock Ted | EVP & Chief Scientific Officer | 03/25/2021 | 465,770 |
Keswani Sanjay | EVP & Chief Medical Officer | 03/24/2021 | 29,917 |
Keswani Sanjay | EVP & Chief Medical Officer | 03/24/2021 | 120,512 |
Lew Jennifer | EVP & Chief Financial Officer | 03/23/2021 | 37,443 |
Lew Jennifer | EVP & Chief Financial Officer | 03/23/2021 | 142,176 |
Clarus Lifesciences III, L.P. | 10% Owner | 07/28/2020 | 3,400,000 |
Bain Capital Life Sciences Investors, LLC | 10% Owner | 07/28/2020 | 6,800,000 |
Lew Jennifer | EVP & Chief Financial Officer | 07/28/2020 | 34,000 |
Satter Muneer A | Director | 07/28/2020 | 3,400,000 |
Flynn James E | 10% Owner | 07/28/2020 | 5,950,000 |
Flynn James E | 10% Owner | 07/28/2020 | 5,950,000 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,999,975 | 0.05% | 112.77% | Other |
BLACKROCK INC. | 3,318,579 | 0.00038% | -2.62% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 922,232 | 0.00044% | 4.84% | Other |
BLACKSTONE INC. | 910,494 | 0.009% | Exited | Other |
UBS OCONNOR LLC | 692,928 | 0.23% | 26.16% | Value |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 583,913 | 0.05% | No change | Other |
RENAISSANCE TECHNOLOGIES LLC | 484,200 | 0.0034% | -13.74% | Other |
UBS OCONNOR LLC | 300,000 (Call) | 0.00056% | Exited | Value |
DRIEHAUS CAPITAL MANAGEMENT LLC | 258,314 | 0.00251% | No change | Growth |
BALYASNY ASSET MANAGEMENT L.P. | 10,107 | 0.00009% | New | Event Driven |
Period of Report: 12/31/2023
10-K/10-Q Filings: View